Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The restructured biotech’s new lead project enters phase 1.
The company will imminently start its third pivotal trial of PF-08634404.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
